argenx SE (ARGX) Presents at Goldman Sachs forty seventh Annual International Healthcare Convention 2026 Transcript


argenx SE (ARGX) Goldman Sachs forty seventh Annual International Healthcare Convention 2026 June 9, 2026 4:00 PM EDT

Firm Contributors

Arjen Lemmen – Vice President of Company Improvement & Technique
Karl Gubitz – Chief Monetary Officer

Convention Name Contributors

Rajan Sharma – Goldman Sachs Group, Inc., Analysis Division

Presentation

Rajan Sharma
Goldman Sachs Group, Inc., Analysis Division

Afternoon, everybody, and thanks for becoming a member of. My identify is Rajan Sharma, European pharma and biotech analyst right here at Goldman Sachs. Very happy to have argenx with us this afternoon for the final hearth of the day. And we have truly bought 2 audio system. We’re fortunate to have 2 audio system at present. We have Karl Gubitz, who’s CFO, who you all in all probability know. After which we even have Arjen Lemmen, who’s Head of Company Improvement. Possibly simply to kick off, Arjen, given that you simply’re in all probability somebody who hasn’t had as a lot time with buyers relative to Karl, perhaps you may simply give a short introduction of your position, your self, and the way that is developed through the years at argenx.

Arjen Lemmen
Vice President of Company Improvement & Technique

Sure. No, completely happy to take action and completely happy to be right here. So my position at argenx is certainly that I head Company Improvement and Technique. I have been with the corporate since 2015. So I joined argenx when it was simply 30 folks on the time with a duty on our Enterprise Improvement deal-making. I finally developed my position in a broader company improvement duty within the CDR management group.

So my group focuses on actually every part associated to 3rd events and deal-making. So the Enterprise Improvement, the partnerships, the alliances are sourcing with suppliers and Company Technique as a complete. So supporting the group, which nations can we enter, which indications can we prioritize does the general portfolio make sense? Which molecule can we



Source link

Related articles

NEO NEXT+ to purchase EnQuest’s UK upstream enterprise for as much as $960 million

(WO) – NEO NEXT+ Vitality has agreed to amass EnQuest’s UK upstream enterprise...

OpenAI CEO Sam Altman says it is ‘onerous to think about the AI business with out Jensen’

The AI business is getting into a brand new period, and never simply due to its fixed stream of latest mannequin releases and discoveries. The AI group should now push ahead with out...

Speakeasy Raises $18.8M to Unify Ticketing, Reservations, and Funds for Dwell Experiences – AlleyWatch

Customers have spent the previous three years shifting their spending from materials objects to experiences, and McKinsey reported that world spending on experiences grew 2.6% between 2023 and 2025, greater than thrice the...

Cathie Wooden’s ARK Sells $85 Million In Nvidia Whereas Shopping for $40 Million In Crypto Shares — What’s Behind The Shift?

Trusted Editorial content material, reviewed by main business specialists and seasoned editors. Advert Disclosure Cathie Wooden’s ARK Make investments has made a placing portfolio adjustment, promoting roughly $84.8 million in Nvidia shares whereas buying...
spot_img

Latest articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

WP2Social Auto Publish Powered By : XYZScripts.com